Type 1 Diabetes Risk Assessment

• Research type

  Research Study

• Full title

  Type 1 Diabetes Risk Assessment: Type 1 Diabetes Risk in Adults (T1DRA) and follow up in those “At Risk” of Autoimmune Diabetes (ARAD).

• IRAS ID

  333462

• Contact name

  Kathleen Gillespie

• Contact email

  k.m.gillespie@bristol.ac.uk

• Sponsor organisation

  University of Bristol

• Duration of Study in the UK

  2 years, 2 months, 13 days

• Research summary

  Recent approval of Teplizumab in the USA to delay onset of clinical diabetes in individuals who are “at risk” (islet autoantibody positive) has resulted in an international drive to identify and follow up “at risk” participants for additional
  clinical trials. This application form describes an “umbrella” ethical approval which will cover:
  Arm 1: recruitment to a recently funded study – Type 1 Diabetes Risk in Adults (T1DRA) focused on identifying individuals over the age of 18 years in the general population who are “at risk” of future type 1 diabetes
  and
  Arm 2: follow up (including invitation to clinical trials/mechanistic studies) of children and adults already identified as
  “At risk of Autoimmune Diabetes (ARAD) but not under active follow-up including through UK Trialnet.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  23/NW/0305

• Date of REC Opinion

  26 Oct 2023

• REC opinion

  Further Information Favourable Opinion